PDL1 expression in desmoplastic melanoma is associated with tumor aggressiveness and progression

Publication date: September 2017
Source:Journal of the American Academy of Dermatology, Volume 77, Issue 3
Author(s): Stefan Kraft, Maria-Teresa Fernandez-Figueras, Nina A. Richarz, Keith T. Flaherty, Mai P. Hoang
BackgroundThe prognostic role of programmed death ligand 1 (PDL1), CD8, and forkhead box p3 (FoxP3) expression in desmoplastic melanomas is unclear.MethodsWe correlated PDL1, p53, and Ki-67 expression with CD8⁺ and FoxP3⁺ immune infiltrates with clinicopathologic variables and patient outcomes in a series of 66 desmoplastic melanomas.ResultsTumoral PDL1 expression (≥25%), which was seen in 21% of patients (14 of 66), significantly correlated with mixed histology, tumor thickness, mitoses, recurrence, and metastasis. According to linear regression analysis, tumoral PDL1 expression correlated with thickness (P = .0041); p53 expression (P = .019); Ki-67 proliferation index (P = .0018); and tumoral CD8 (P = .0084), stromal CD8 (P < .0001), and FoxP3 (P < .0001) T-cell counts. According to univariate analyses, PDL1 expression of 25% or higher correlated with shorter progression-free survival (P < .0001) and melanoma-specific survival (P = .034). According to multivariate analyses, PDL1 expression of 25% or more (P = .026) and mixed histology (P = .039) independently predicted shorter progression-free survival, and presence of lymphovascular invasion predicted shorter overall survival (P = .018).LimitationsSmall study size.ConclusionTumoral and stromal CD8⁺ and FoxP3⁺ lymphocyte counts correlated with tumoral PDL1 expression, which is supportive of an adaptive immune response. PDL1 expression in desmoplastic melanoma was associated with tumor aggressiveness and progression. Although PDL1 expression is typically low in melanoma, its frequency and level of expression in desmoplastic melanoma may identify a subset of melanomas that are likely to respond to immunotherapy.



http://ift.tt/2fBqQjm